NCT05048069 - Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab. | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2024

Conditions

Acute GastritisChronic Gastritis

Interventions

DRUG

Mucosta®SR Tablets 150mg(Rebamipide)

adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.

Trial Locations (1)

Unknown

RECRUITING

Soon Chun Hyang University Hospital Seoul, Seoul